Introducing GOSH Sample Bank

13 Nov 2019, 3:28 p.m.

At GOSH, we want research to be embedded in everything we do. That’s why we’ve launched the GOSH Sample Bank, where patients’ leftover samples can be used in child health research instead of being thrown away. This will allow us to carry out even more cutting-edge research, helping us better understand rare conditions and develop the treatments of the future.

Research, not rubbish 

When patients come to GOSH, they often need to give samples such as urine, blood, faeces or biopsies of skin or other tissue. After all the tests have been carried out, any leftover sample is thrown away safely. But these biological samples could hold important clues to the underlying causes of rare diseases. So we’re asking patients to consider donating their leftover samples to the Sample Bank.

The samples will be processed, frozen and stored at GOSH and once we’ve built up enough samples, researchers at GOSH and our academic partner the UCL Great Ormond Street Institute of Child Health, can then request to use the samples in their research.

“The GOSH Sample Bank will be invaluable for researchers studying rare childhood diseases. In the future, the findings from analysis of these samples could really make a difference to the way that we understand, diagnose and treat rare conditions in children,” Professor David Goldblatt, Director of Research and Innovation, said.

The power of sample banks 

Collecting biological samples for specific research projects has been carried out for many years at GOSH and allowed us to make some major breakthroughs. The difference with the GOSH Sample Bank is that we will be asking patients to donate leftover samples that have the potential to be used in a range of research projects. We won’t be asking patients to donate anything extra or do any extra tests.

Although we have an idea what the Sample Bank will help us investigate, it will allow samples to be analysed in ways researchers haven’t even thought of yet. Sample banks particularly important for specialist hospitals like GOSH where it can be hard to get enough samples to allow researchers to study rare conditions

It will take some time for us to build up our bank of rare disease samples, and research itself can be a slow process, so we are not expecting breakthroughs immediately. But in the future we hope the GOSH Sample Bank will become a rich resource of information, helping researchers answer important questions about why conditions occur and who is at risk. These answers can lead to quicker and more accurate diagnoses, better treatments for children and, ultimately, help more children fulfil their potential.

How to get involved

- Speak to your doctors or nurses to find out if Sample Bank is recruiting in your clinical area.

- Watch our new animation featuring a voiceover from 17-year-old GOSH patient and Young Persons’ Advisory Group member Sandra.

Find out more about the GOSH Sample Bank.

Ancient gene mutation found as the cause of rare hereditary condition for GOSH patient.

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

Leukaemia trial shows promise and complexity of genome-edited cell therapies

A ‘one size fits all’ immune therapy developed at the UCL Great Ormond Street Institute of Child Health (ICH) could help to clear cancerous cells in children and adults who have exhausted all other treatment options for B-cell acute lymphoblastic leukaemi

GOSH researchers join experts in warning of the detrimental impact of a no deal Brexit on rare diseases

Experts have warned that a ‘no deal’ Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly spe

Promising early results in CAR T-cell trial for common childhood cancer

Results from a phase I clinical trial Involving the UCL Great Ormond Street Institute of Child Health (ICH) show that CAR T-cell therapy could achieve activity against neuroblastoma tumours, opening the door to progress this approach towards further clini